Capital Performance Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Capital Performance Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.5K	Buy	26,051 +76	+0.3%	+$189	﹤0.01%	462
2025 Q4	$46.8K	Hold	25,975	–	–	﹤0.01%	443
2025 Q3	$57.7K	Sell	25,975 -1	-0%	-$2	0.01%	344
2025 Q2	$38.4K	Hold	25,976	–	–	0.01%	268
2025 Q1	$66.5K	Hold	25,976	–	–	0.01%	255
2024 Q4	$48.8K	Hold	25,976	–	–	0.02%	161
2024 Q3	$26.5K	Sell	25,976 -817	-3%	-$859	0.01%	520
2024 Q2	$31.3K	Buy	26,793 +535	+2%	+$632	0.01%	90
2024 Q1	$33.1K	Buy	26,258 +283	+1%	+$423	0.01%	83
2023 Q4	$46.2K	Buy	25,975 +1	+0%	+$2	0.02%	76
2023 Q3	$43.1K	Hold	25,974	–	–	0.02%	56
2023 Q2	$51.9K	Hold	25,974	–	–	0.03%	59
2023 Q1	$54.5K	Hold	25,974	–	–	0.03%	53
2022 Q4	$35.6K	Hold	25,974	–	–	0.02%	50
2022 Q3	$27K	Hold	25,974	–	–	0.02%	45
2022 Q2	$28K	Buy	+25,974	New	+$30.4K	0.02%	46

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Capital Performance Advisors's PLX Position: Q1 2026 in Review

Capital Performance Advisors increased its Protalix BioTherapeutics (PLX) stake by 0.29% in Q1 2026, buying an estimated $189 and bringing the position to 26,051 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #462.

Capital Performance Advisors first reported a position in PLX in Q2 2022 and has held it in 16 quarters since. The position peaked at $66.5K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Capital Performance Advisors held 26,051 shares of Protalix BioTherapeutics worth $56.5K as of Q1 2026.
Capital Performance Advisors bought 76 Protalix BioTherapeutics shares in Q1 2026, an estimated $189.
Protalix BioTherapeutics made up ﹤0.01% of Capital Performance Advisors's portfolio in Q1 2026, its #462 holding.
Capital Performance Advisors first reported a position in Protalix BioTherapeutics in Q2 2022 and has held it in 16 quarters since.
Capital Performance Advisors's Protalix BioTherapeutics position peaked at $66.5K in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.